AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17768687 — intervention group
Group type: COMPARATOR
Intervention: Creativity-oriented ergotherapy group
Number of subjects: 227
Study 16336326 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (MVAC/MVEC)
Number of subjects: 49
Study 16336326 — intervention group
Group type: COMPARATOR
Intervention: Control (observation only)
Number of subjects: 49
Study 12953657 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg/d)
Number of subjects: 33
Study 12953657 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg/d)
Number of subjects: 33
Study 12953657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200 mg/d)
Number of subjects: 33
Study 12953657 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 33
Study 10848646 — intervention group
Group type: EXPERIMENTAL
Intervention: Short programme (SP) - trained every day for 2 weeks
Number of subjects: 10
Study 10848646 — intervention group
Group type: EXPERIMENTAL
Intervention: Long programme (LP) - trained over a 6-week period with a 2-day rest period after each training session
Number of subjects: 10
Study 8872623 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) at different force levels (5, 10, 20, 40, and 60% MVC)
Number of subjects: 11
Study 1322162 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily
Number of subjects: 12
Study 1322162 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 10 mg once daily
Number of subjects: 12
Study 1322162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 12
Study 1322162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6528870 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation
Number of subjects: 108
Study 6528870 — intervention group
Group type: COMPARATOR
Intervention: Physician regulation
Number of subjects: 108
Study 31830258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100,000 IU (n=25)
Number of subjects: 48
Study 31830258 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=23)
Number of subjects: 48
Study 29799099 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC 100 mg
Number of subjects: 334
Study 29799099 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC 150 mg
Number of subjects: 334
Study 29799099 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC 200 mg
Number of subjects: 334
Study 29799099 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 100 mg
Number of subjects: 334
Study 29799099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 27811556 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (mean dosage 44.4 mg/d, range 20-60 mg/d)
Number of subjects: 46
Study 27811556 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (mean dosage 123.8 mg/d, range 50-200 mg/d)
Number of subjects: 46
Study 24533896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 144
Study 24533896 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 144
Study 24533896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 24533896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (normal pH subgroup)
Number of subjects: 144
Study 24533896 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (normal pH subgroup)
Number of subjects: 144
Study 24533896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal pH subgroup)
Number of subjects: 144
Study 24533896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (abnormal pH subgroup)
Number of subjects: 144
Study 24533896 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (abnormal pH subgroup)
Number of subjects: 144
Study 24533896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (abnormal pH subgroup)
Number of subjects: 144
Study 22902194 — intervention group
Group type: EXPERIMENTAL
Intervention: Side‐posture SMT (n = 30)
Number of subjects: 40
Study 22902194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavitating joints
Number of subjects: 40
Study 22902194 — intervention group
Group type: COMPARATOR
Intervention: Side‐posture positioning (SPP, n = 10)
Number of subjects: 40
Study 19155748 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (8.5 mg immediate release and 1.5 mg sustained release)
Number of subjects: 41
Study 19155748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 17484223 — intervention group
Group type: COMPARATOR
Intervention: Inactivated Polio Vaccine (IPV)
Number of subjects: 9544
Study 17484223 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles Vaccine (MV)
Number of subjects: 9544
Study 17484223 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV after receiving MV at 9 months or later
Number of subjects: 9544
Study 17484223 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccination status at enrollment
Number of subjects: 9544
Study 17484223 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles Vaccine (MV) as the most recent vaccine
Number of subjects: 9544
Study 15492297 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-slice MDCT
Number of subjects: 33
Study 15492297 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-slice MDCT (restricted to proximal coronary segments)
Number of subjects: 33
Study 15492297 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-slice MDCT (restricted to segments with excellent image quality)
Number of subjects: 33
Study 15492297 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-slice MDCT (patient-based model)
Number of subjects: 33
Study 15492297 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary calcification
Number of subjects: 33
Study 12001536 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG (group I)
Number of subjects: 106
Study 12001536 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG (group II)
Number of subjects: 106
Study 9682111 — intervention group
Group type: EXPERIMENTAL
Intervention: lovision 127
Number of subjects: 133
Study 9682111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor ORC MemoryLens
Number of subjects: 133
Study 9682111 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcon AcrySof MA30BA
Number of subjects: 133
Study 9682111 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergan PhacoFlex II
Number of subjects: 133
Study 8025424 — intervention group
Group type: EXPERIMENTAL
Intervention: Belmont 1992
Number of subjects: 2260
Study 8025424 — intervention group
Group type: EXPERIMENTAL
Intervention: Wagga Wagga 1992
Number of subjects: 2260
Study 8025424 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic children
Number of subjects: 2260
Study 8025424 — intervention group
Group type: EXPERIMENTAL
Intervention: Belmont
Number of subjects: 2260
Study 8025424 — intervention group
Group type: EXPERIMENTAL
Intervention: Wagga Wagga
Number of subjects: 2260
Study 2505996 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid suspension (10 ml)
Number of subjects: 8
Study 2505996 — intervention group
Group type: COMPARATOR
Intervention: No antacid
Number of subjects: 8
Study 963493 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole (300 mg twice daily for 7 days)
Number of subjects: 112
Study 963493 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (200 mg three times a day for 7 days)
Number of subjects: 112
Study 963493 — intervention group
Group type: COMPARATOR
Intervention: Antigonococcal therapy (one-day treatment with ampicillin or single-dose therapy with doxycycline)
Number of subjects: 112
Study 963493 — intervention group
Group type: COMPARATOR
Intervention: Antitrichomonal therapy
Number of subjects: 112
Study 31694611 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-ECT (3 ECT sessions followed by LCE sessions, approximately 2.8 joules per session)
Number of subjects: 112
Study 31694611 — intervention group
Group type: COMPARATOR
Intervention: Conventional ECT (control group)
Number of subjects: 112
Study 28249141 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 405
Study 28249141 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 405
Study 26527789 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy boost (arm A)
Number of subjects: 246
Study 26527789 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (arm B)
Number of subjects: 246
Study 26527789 — intervention group
Group type: COMPARATOR
Intervention: Overall (all patients)
Number of subjects: 246
Study 24352394 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of right and left maxillary first premolars (G1)
Number of subjects: 12
Study 24352394 — intervention group
Group type: COMPARATOR
Intervention: Non-extraction (G2)
Number of subjects: 12
Study 21440872 — intervention group
Group type: EXPERIMENTAL
Intervention: HSS plus furosemide (250 mg) and light sodium restriction (120 mmol)
Number of subjects: 133
Study 21440872 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (250 mg) alone with low sodium diet (80 mmol)
Number of subjects: 133
Study 19806919 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg
Number of subjects: 0
Study 19806919 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg
Number of subjects: 0
Study 19806919 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg
Number of subjects: 0
Study 19806919 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone multiple doses 50 mg
Number of subjects: 0
Study 16958566 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 11
Study 16958566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 12975670 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin combination
Number of subjects: 0
Study 12975670 — intervention group
Group type: COMPARATOR
Intervention: M-VAC combination chemotherapy
Number of subjects: 0
Study 10919743 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of flaxseed
Number of subjects: 16
Study 10919743 — intervention group
Group type: COMPARATOR
Intervention: 28 g of wheat bran
Number of subjects: 16
Study 10919743 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of flaxseed plus 28 g of wheat bran
Number of subjects: 16
Study 10919743 — intervention group
Group type: COMPARATOR
Intervention: No flaxseed or wheat bran
Number of subjects: 16
Study 8829030 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 0
Study 8829030 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 0
Study 1416236 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy (S2) Alastik separators
Number of subjects: 21
Study 1416236 — intervention group
Group type: COMPARATOR
Intervention: Placebo (separator placed and removed)
Number of subjects: 21
Study 1416236 — intervention group
Group type: COMPARATOR
Intervention: Control (no separator)
Number of subjects: 21
Study 2859739 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 30
Study 2859739 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 30
Study 2859739 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg (control)
Number of subjects: 30
Study 30130991 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 30‐min seminar about the 'One Stretch' exercise
Number of subjects: 4767
Study 30130991 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: B + physical and psychological approaches to LBP treatment
Number of subjects: 4767
Study 30130991 — intervention group
Group type: COMPARATOR
Intervention: Group A: Control group
Number of subjects: 4767
Study 29681489 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted fundoscopy
Number of subjects: 101
Study 28049599 — intervention group
Group type: EXPERIMENTAL
Intervention: Bileaflet aortic valve replacement
Number of subjects: 39
Study 28049599 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement (MVR)
Number of subjects: 39
Study 26683621 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine tone assessment by a skilled birth attendant (midwife)
Number of subjects: 800
Study 26683621 — intervention group
Group type: COMPARATOR
Intervention: Uterine tone self-assessment
Number of subjects: 800
Study 24461758 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing
Number of subjects: 47
Study 22017169 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopontin levels in men (mean ± SD: 60.7 ± 15.6 μg/mL)
Number of subjects: 1817
Study 22017169 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopontin levels in women (mean ± SD: 51.7 ± 16.0 μg/mL)
Number of subjects: 1817
Study 18452361 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive maxillary plates during the first year of life (Group IO+)
Number of subjects: 54
Study 18452361 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Group IO-)
Number of subjects: 54
Study 16541086 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 28
Study 12712082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytologic testing
Number of subjects: 117
Study 12712082 — intervention group
Group type: COMPARATOR
Intervention: Histologic interpretation
Number of subjects: 117
Study 12712082 — intervention group
Group type: COMPARATOR
Intervention: Cytologic/histologic pairs
Number of subjects: 117
Study 12712082 — intervention group
Group type: COMPARATOR
Intervention: Progression to high-grade lesions
Number of subjects: 117
Study 10757134 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.62 g/kg of alcohol
Number of subjects: 56
Study 10757134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9282804 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of acetazolamide (Diamox) intravenous injection
Number of subjects: 50
Study 8350585 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 21
Study 8350585 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 21
Study 8350585 — intervention group
Group type: COMPARATOR
Intervention: Positioning changes (prone/supine)
Number of subjects: 21
Study 2881901 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study 2881901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29226816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous furosemide (IV), mean dose: 123 ± 47 mg
Number of subjects: 41
Study 29226816 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous furosemide (SC), fixed dose of 80 mg over 5 h
Number of subjects: 41
Study 29226816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous furosemide (IV)
Number of subjects: 41
Study 29226816 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous furosemide (SC)
Number of subjects: 41
Study 27938870 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured antenatal programme
Number of subjects: 0
Study 27938870 — intervention group
Group type: COMPARATOR
Intervention: Auditorium-based lectures
Number of subjects: 0
Study 24923685 — intervention group
Group type: EXPERIMENTAL
Intervention: 91-day extended regimen combined oral contraceptive (150 μg levonorgestrel [LNG]/30 μg ethinylestradiol [EE] for 84 days, followed by 10 μg EE for seven days)
Number of subjects: 187
Study 24923685 — intervention group
Group type: COMPARATOR
Intervention: Traditional 21/7 regimen (21 days 150 μg LNG/30 μg EE)
Number of subjects: 187
Study 24923685 — intervention group
Group type: COMPARATOR
Intervention: Traditional 21/7 regimen (150 μg desogestrel [DSG]/30 μg EE)
Number of subjects: 187
Study 24315267 — intervention group
Group type: EXPERIMENTAL
Intervention: Music provided by an iPod
Number of subjects: 25
Study 24315267 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 25
Study 21702861 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning every three hours at night using the 30° tilt (experimental group)
Number of subjects: 213
Study 21702861 — intervention group
Group type: COMPARATOR
Intervention: Routine prevention (six-hourly repositioning using 90° lateral rotation) (control group)
Number of subjects: 213
Study 18840106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 microg/kg fentanyl injected over 2 s
Number of subjects: 476
Study 18840106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 microg/kg fentanyl injected over 5 s
Number of subjects: 476
Study 18840106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 microg/kg fentanyl injected over 10 s
Number of subjects: 476
Study 18840106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 476
Study 17070152 — intervention group
Group type: EXPERIMENTAL
Intervention: Community hospital (n = 305)
Number of subjects: 609
Study 17070152 — intervention group
Group type: COMPARATOR
Intervention: Regional hospital (n = 304)
Number of subjects: 609
Study 17070152 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluded high-risk PCI patients
Number of subjects: 609
Study 17070152 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 609
Study 12568305 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus dexamethasone (GS group)
Number of subjects: 50
Study 12568305 — intervention group
Group type: COMPARATOR
Intervention: Granisetron alone (G group)
Number of subjects: 50
Study 10898118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.8 mg
Number of subjects: 1170
Study 10898118 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin 0.4 mg
Number of subjects: 1170
Study 10898118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1170
Study 9352727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive neurodevelopmental therapy (NDT) plus casting
Number of subjects: 0
Study 9352727 — intervention group
Group type: COMPARATOR
Intervention: Regular occupational therapy (OT) program
Number of subjects: 0
Study 8470384 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminders attempted the evening before scheduled visits (intervention group).
Number of subjects: 497
Study 8470384 — intervention group
Group type: COMPARATOR
Intervention: No telephone reminders (control group).
Number of subjects: 497
Study 3013704 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate, high fibre diet (55% of total energy) for six weeks
Number of subjects: 0
Study 3013704 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate diet (35% of total energy) for six weeks
Number of subjects: 0
Study 3013704 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate, high fibre diet (55% of total energy)
Number of subjects: 0
Study 3013704 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate diet (35% of total energy)
Number of subjects: 0
Study 30354590 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stents (BP-SES)
Number of subjects: 2902
Study 30354590 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents (DP-EES)
Number of subjects: 2902
Study 27282262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling bottle
Number of subjects: 1701
Study 27282262 — intervention group
Group type: COMPARATOR
Intervention: Conventional container
Number of subjects: 1701
Study 24986270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cure‐allergic‐rhinitis Syrup (CS)
Number of subjects: 249
Study 24986270 — intervention group
Group type: EXPERIMENTAL
Intervention: Yu‐ping‐feng San (YS)
Number of subjects: 249
Study 24986270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 22778123 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention targeting general practitioners (practice audit with personalized automated feedback, printed educational material, and newsletters over 2 years)
Number of subjects: 21762
Study 22778123 — intervention group
Group type: COMPARATOR
Intervention: Control group (practice audit without individualized feedback and newsletters without educational material)
Number of subjects: 21762
Study 22778123 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention targeting general practitioners
Number of subjects: 21762
Study 20540806 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture (2 times a week for a total of 12 sessions over 6 weeks)
Number of subjects: 0
Study 20540806 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (same frequency and duration as real acupuncture)
Number of subjects: 0
Study 18677276 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position (RTP) at 10 degrees during surgery
Number of subjects: 60
Study 18677276 — intervention group
Group type: COMPARATOR
Intervention: Supine position (control group)
Number of subjects: 60
Study 20801498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 10285
Study 20801498 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10285
Study 15663667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 589
Study 15663667 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 589
Study 12419747 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan plus gemcitabine (Topotecan initial dose 0.5 mg/m2 daily for days 1-5, gemcitabine 800 mg/m2 on day 1 and 600 mg/m2 on day 8)
Number of subjects: 21
Study 12419747 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan plus gemcitabine
Number of subjects: 21
Study 9869553 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical autonomic symptoms
Number of subjects: 138
Study 9869553 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent ankle reflexes
Number of subjects: 138
Study 9869553 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic changes of an axonal neuropathy
Number of subjects: 138
Study 9869553 — intervention group
Group type: EXPERIMENTAL
Intervention: Demyelinating neuropathy
Number of subjects: 138
Study 7635028 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine enema (Pentasa-Yamanouchi Pharma)
Number of subjects: 0
Study 7635028 — intervention group
Group type: COMPARATOR
Intervention: Oral formulations of mesalazine
Number of subjects: 0